S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Buy THIS stock before Taiwan is attacked (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Buy THIS stock before Taiwan is attacked (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Buy THIS stock before Taiwan is attacked (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Buy THIS stock before Taiwan is attacked (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Buy THIS stock before Taiwan is attacked (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Buy THIS stock before Taiwan is attacked (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Buy THIS stock before Taiwan is attacked (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Buy THIS stock before Taiwan is attacked (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:ACIU

AC Immune - ACIU Stock Forecast, Price & News

$2.22
+0.03 (+1.37%)
(As of 03/24/2023 08:50 PM ET)
Add
Compare
Today's Range
$2.16
$2.23
50-Day Range
$2.14
$2.49
52-Week Range
$1.68
$4.84
Volume
86,500 shs
Average Volume
172,979 shs
Market Capitalization
$185.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

AC Immune MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
485.6% Upside
$13.00 Price Target
Short Interest
Healthy
0.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.26mentions of AC Immune in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.78) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

551st out of 995 stocks

Pharmaceutical Preparations Industry

259th out of 482 stocks


ACIU stock logo

About AC Immune (NASDAQ:ACIU) Stock

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

ACIU Stock News Headlines

AC Immune (NASDAQ:ACIU) Upgraded by StockNews.com to Hold
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
SVB Securities Sticks to Their Buy Rating for AC Immune SA (ACIU)
HC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
AC Immune Earnings Preview
AC Immune Could Reload On Upcoming Readout
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
See More Headlines
Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

ACIU Company Calendar

Last Earnings
11/08/2021
Today
3/26/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACIU
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+485.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-74,140,000.00
Pretax Margin
-1,797.91%

Debt

Sales & Book Value

Annual Sales
$4.12 million
Book Value
$2.12 per share

Miscellaneous

Free Float
79,709,000
Market Cap
$185.48 million
Optionable
Not Optionable
Beta
0.59

Key Executives

  • Andrea Pfeifer
    Chief Executive Officer & Director
  • Christopher Roberts
    Chief Financial Officer & Associate VP-Finance
  • Oliver Sol
    VP & Head-Clinical Development
  • Piergiorgio Donati
    Chief Technical Operations Officer
  • Marie Kosco-Vilbois
    Chief Scientific Officer













ACIU Stock - Frequently Asked Questions

Should I buy or sell AC Immune stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACIU shares.
View ACIU analyst ratings
or view top-rated stocks.

What is AC Immune's stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month price targets for AC Immune's stock. Their ACIU share price forecasts range from $10.00 to $16.00. On average, they anticipate the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 485.6% from the stock's current price.
View analysts price targets for ACIU
or view top-rated stocks among Wall Street analysts.

How have ACIU shares performed in 2023?

AC Immune's stock was trading at $2.04 at the start of the year. Since then, ACIU shares have increased by 8.8% and is now trading at $2.22.
View the best growth stocks for 2023 here
.

When is AC Immune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our ACIU earnings forecast
.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03.

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?
When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

Who are AC Immune's major shareholders?

AC Immune's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (2.33%), Platinum Investment Management Ltd. (1.30%), Wells Fargo & Company MN (0.87%), Assenagon Asset Management S.A. (0.71%), Renaissance Technologies LLC (0.48%) and Avidity Partners Management LP (0.39%).

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $2.22.

How much money does AC Immune make?

AC Immune (NASDAQ:ACIU) has a market capitalization of $185.48 million and generates $4.12 million in revenue each year. The company earns $-74,140,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does AC Immune have?

The company employs 137 workers across the globe.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The official website for the company is www.acimmune.com. The company can be reached via phone at (121) 345-9121, via email at ir@acimmune.com, or via fax at 41-21-345-9120.

This page (NASDAQ:ACIU) was last updated on 3/27/2023 by MarketBeat.com Staff